Pharmacogenomic associations of adverse drug reactions inasthma: systematic review and research prioritisation

A systematic review of pharmacogenomic studies capturing adverse drug reactions (ADRs) related to asthma medications was undertaken, and a survey of Pharmacogenomics in Childhood Asthma (PiCA) consortia members was conducted. Studies were eligible if genetic polymorphisms were compared with suspecte...

Full description

Saved in:
Bibliographic Details
Published in:The pharmacogenomics journal 2020-10, Vol.20 (5), p.621-628
Main Authors: King, Charlotte, McKenna, Amanda, Farzan Niloufar, Vijverberg, Susanne J, van der Schee Marc P, Maitland-van der Zee Anke H, Lambang, Arianto, Bisgaard, Hans, BØnnelykke Klaus, Berce Vojko, PotoČnik Uros, Repnik Katja, Carleton, Bruce, Daley, Denise, Chew, Fook Tim, Chiang, Wen Chin, Sio Yang Yie, Cloutier, Michelle M, Den Dekker Herman T, Duijts Liesbeth, de Jongste Johan C, Nicole, Dijk F, Flores, Carlos, Hernandez-Pacheco, Natalia, Mukhopadhyay Somnath, Basu Kaninika, Tantisira Kelan G, Verhamme, Katia M, Celedón, Juan C, no Erick, Canino Glorisa, Francis, Ben, Pirmohamed Munir, Sinha, Ian, Hawcutt, Daniel B
Format: Article
Language:English
Subjects:
Anaphylactoid reactions
Asthma
Bone mineral density
Children
Consortia
Corticosteroids
Gene polymorphism
Nausea
Pharmacogenomics
Respiratory function
Sleep
Systematic review
Tachycardia
Theophylline
Vomiting
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A systematic review of pharmacogenomic studies capturing adverse drug reactions (ADRs) related to asthma medications was undertaken, and a survey of Pharmacogenomics in Childhood Asthma (PiCA) consortia members was conducted. Studies were eligible if genetic polymorphisms were compared with suspected ADR(s) in a patient with asthma, as either a primary or secondary outcome. Five studies met the inclusion criteria. The ADRs and polymorphisms identified were change in lung function tests (rs1042713), adrenal suppression (rs591118), and decreased bone mineral density (rs6461639) and accretion (rs9896933, rs2074439). Two of these polymorphisms were replicated within the paper, but none had external replication. Priorities from PiCA consortia members (representing 15 institution in eight countries) for future studies were tachycardia (SABA/LABA), adrenal suppression/crisis and growth suppression (corticosteroids), sleep/behaviour disturbances (leukotriene receptor antagonists), and nausea and vomiting (theophylline). Future pharmacogenomic studies in asthma should collect relevant ADR data as well as markers of efficacy.
ISSN:1470-269X
1473-1150
DOI:10.1038/s41397-019-0140-y